Table 2.

Atorvastatin, in combination with sulindac or naproxen, decreases mucosal and colonic tumor levels of the proinflammatory cytokines, TNF-α, IL-1β, and IL-4

Experimental groupaTNF-α, pg/mgIL-1β, pg/mgIL-4, pg/mg
AOM-control (AIN-76A) diet1,182.9 ± 114.92,194.7 ± 209.4321.0 ± 35.6
AOM-sulindac (100 ppm)754.1 ± 64.7 (P = 0.004)1,610.0 ± 173.0 (P = 0.04)212.4 ± 26.4 (P = 0.02)
AOM-naproxen (150 ppm)910.7 ± 85.51,917.9 ± 316.6292.5 ± 51.1
AOM-atorvastatin (200 ppm)812.8 ± 117.7 (P = 0.03)1,431.3 ± 195.1 (P = 0.01)186.2 ± 30.8 (P = 0.01)
AOM-atorvastatin (100 ppm) + sulindac (100 ppm)747.7 ± 109.2 (P = 0.03)1,410.9 ± 200.7 (P = 0.01)193.9 ± 39.2 (P = 0.03)
AOM-atorvastatin (100 ppm) + naproxen (150 ppm)759.7 ± 205.0 (P = 0.01)1,499.9 ± 226.7 (P = 0.03)191.7 ± 29.8 (P = 0.01)
  • aThe mucosa samples were homogenized and assayed by ELISA for the different cytokines, as described under Materials and Methods. Colon mucosa samples were randomly selected from each group and cytokine levels were analyzed (n = 12). The mean ± SD values are shown.